Question: What is the top priority of the company that was formerly known as EyeTech Pharmaceuticals?

Context articles: Pegaptanib
Battle of Misrata
Team Downey
Actavis
Apoteket
1962 Asian Games medal table
Sterling Drug
List of Superfund sites in Texas
Intas Biopharmaceuticals
OSI Pharmaceuticals

Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD).
 It was discovered by NeXstar Pharmaceuticals and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.
 Outside the US pegaptanib is marketed by Pfizer.
 Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.
The Battle of Misrata (Arabic: معركة مصراتة‎ ‎ ), also known as the Siege of Misrata, was a battle of the 2011 Libyan Civil War for the control of Misrata.
 It was fought between troops loyal to the government of Muammar Gaddafi, and anti-Gaddafi rebels who held Misrata, the third largest city in Libya.
 Following the initial stages of the uprising, the Libyan government took back most towns in the west of the country, leaving Misrata the only major city under rebel control in Tripolitania.
 The city soon became the site of one of the war's major battles.
 The suffering of Misrata's citizens gained worldwide attention.
 The intensity of fighting, and its importance both strategic and symbolic, earned the battle notice as 'Libya's Stalingrad'.
 During the siege, the city saw very heavy fighting, came under daily assaults and shelling, and was at times cut off from its seaport, leaving no escape route for Misrata's inhabitants.
 Following UN military intervention in the civil war, NATO declared that breaking the encirclement of the city was its top priority.
 It ranks as one of the longest and bloodiest battles of the entire war.
 In late April and early May, rebel counterattacks successfully retook the city, culminating in the fall of the airport and nearby military airbase on 11 May.
Team Downey is an American production company founded by Robert Downey Jr. and Susan Downey that produces film and television properties.
 David Gambino is the president of production.
 Team Downey was based at Warner Bros. since its founding in 2010, but left in October 2016.
 It will still be part of Warner Bros' "top priority projects" such as a live-action adaptation of "Pinocchio", and the sequel to "".
Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis, plc, prior to the acquisition of Allergan, inc) is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
 Actavis has a commercial presence across approximately 100 countries.
 The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Apoteket AB is a state-owned pharmaceuticals retailer in Sweden which formerly held a monopoly on the retail sale of medicines in the country.
 Formerly known as Apoteksbolaget, the company is a government owned enterprise reporting to the Ministry of Finance.
The 1962 Asian Games, officially known as the Fourth Asian Games, was a multi-sport event held in Jakarta, Indonesia, from 24 August to 4 September 1962.
 This edition of the Asian Games was a subject of major international controversy when the host nation denied two Asian Games Federation members, Republic of China and Israel, to participate in the Games.
 Consequently, the International Olympic Committee revoked the Indonesia's membership and barred it from participating in the 1964 Summer Olympics in Tokyo.
 The Games and related infrastructure development projects in Jakarta were heavily funded by the Soviet Union and were given "top priority" by the then-President of Indonesia, Sukarno.
Sterling Drug was an American global pharmaceutical company, known as Sterling-Winthrop, Inc. after the merger with Winthrop-Stearns Inc. (which resulted from the merger of "Winthrop Chemical Company Inc." and "Frederick Stearns & Company").
 It was formerly known as "Sterling Winthrop Pharmaceuticals", whose primary product lines included diagnostic imaging agents, hormonal products, cardiovascular products, analgesics, antihistamines and muscle relaxants.
This is a list of Superfund sites in Texas designated under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) environmental law.
 The CERCLA federal law of 1980 authorized the United States Environmental Protection Agency (EPA) to create a list of polluted locations requiring a long-term response to clean up hazardous material contaminations.
 These locations are known as Superfund sites, and are placed on the National Priorities List (NPL).
 The NPL guides the EPA in "determining which sites warrant further investigation" for environmental remediation.
 As of March 17, 2016, there are 51 Superfund sites on the National Priorities List in Texas.
 One new site has been proposed for inclusion on the list.
 Twelve additional sites have been cleaned up and are considered deleted, with no further action required.
 One NPL site included in this list, Motco, Inc., has been designated as the state's Top Priority Site.
 According to CERCLA, states may make only one such designation and is one that the State has identified as presenting the greatest danger to public health, welfare, or the environment among the known facilities in that State.
The Biologics Business Unit (BU) of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as Intas Biopharmaceuticals Ltd.
 Intas Pharmaceuticals limited is an Indian company headquartered in Ahmedabad, India.
 The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading biosimilar product manufacturers in Asia.
OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom.
 OSI specializes in the discovery and development of molecular targeted therapies.
 Though oncology is the top priority for OSI, research and development targeting type 2 diabetes and obesity is conducted through their U.K. subsidiary Prosidion Limited.
 OSI has also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen (Pegaptanib) for Age-related macular degeneration; however, acquisition of the firm Eyetech, meant to provide control over this product and diversify the company, has been unsuccessful, ending in divestiture.